Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
Coloplast AS (OTCPK:CLPBY) Tangible Book per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Coloplast AS Tangible Book per Share Related Terms
Coloplast AS Tangible Book per Share Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Tangible Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Tangible Book per Share Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
What does a Tangible Book per Share of $-1.00 mean?
Coloplast AS (CLPBY) has a Tangible Book per Share of $-1.00 as of Mar. 2026. Tangible book per share equals the per-share value of a company's tangible equity. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Tangible Book per Share too high?
Coloplast AS's current Tangible Book per Share is $-1.00. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Tangible Book per Share compare to ISRG and BDX?
Coloplast AS's Tangible Book per Share of $-1.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tangible Book per Share for a Medical Devices & Instruments company?
A good Tangible Book per Share depends on the Medical Devices & Instruments industry context. However, Tangible Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tangible Book per Share mean?
A high Tangible Book per Share can signal that a stock is expensive relative to its fundamentals. Tangible book per share equals the per-share value of a company's tangible equity. View historical data on Coloplast AS and its competitors. Coloplast AS's current Tangible Book per Share is $-1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.72 — trading 48.5% below its estimated fair value. The current Tangible Book per Share is $-1.00. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tangible Book per Share calculated?
Tangible Book per Share is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Tangible Book per Share is $-1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.72 is trading 48.5% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Tangible Book per Share: $-1.00
GF Value™: $13.05 vs. price of $6.72 (48.5% below fair value)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Tangible Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
